ALLO

Allogene Therapeutics Stock Analysis

AI Rating

Good
  • Quality1/10
  • Growth↑ 7/10
  • Value↓ 4/10
Allogene Therapeutics sales and earnings growth
ALLO Growth
Good
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 37.40%
  • FCF Y/Y↑ 44.72%
Allogene Therapeutics gross and profit margin trends
ALLO Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -52.26%
Allogene Therapeutics net debt vs free cash flow
ALLO Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -140.8

Allogene Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks